Recursion Pharmaceuticals Inc (OQ:RXRX)

Apr 16, 2024 08:00 am ET
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will...
Apr 02, 2024 08:00 am ET
Recursion to Participate in Upcoming Investor Conference
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: 23rd Annual Needham Virtual Healthcare Conference –...
Mar 26, 2024 08:00 am ET
Recursion Publishes Annual Environmental, Social and Governance Report
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced the release of its third annual Environmental, Social and Governance (ESG) Report. The report...
Mar 11, 2024 04:00 am ET
Recursion Announces Plans to Open New Office in London
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood. Set to formally open in June 2024, the...
Mar 01, 2024 02:58 pm ET
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Disease Day event at its headquarters on February 29 and virtually in partnership with Alliance to...
Mar 01, 2024 07:59 am ET
Recursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media and Telecom...
Feb 27, 2024 04:05 pm ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023. “2023 was a...
Feb 20, 2024 07:59 am ET
Recursion to Host Public L(earnings) Call on February 27
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2023 financial results on Tuesday,...
Feb 14, 2024 08:31 am ET
Thinking about buying stock in BioNexus Gene Lab, Gladstone Investment Corp, Canopy Growth Corp, Recursion Pharmaceuticals, or Monolithic Power Systems?
NEW YORK, Feb. 14, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BGLC, GAIN, CGC, RXRX, and MPWR.
Jan 24, 2024 09:00 am ET
Altitude Lab Startups Raise Over $120M in Capital
Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab was founded by Recursion to support burgeoning startups and underrepresented entrepreneurs in Utah...
Jan 16, 2024 08:31 am ET
Thinking about buying stock in Carrols Restaurant Group, Atreca Inc, Energy Transfer, Agenus, or Recursion Pharmaceuticals?
NEW YORK, Jan. 16, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAST, BCEL, ET, AGEN, and RXRX.
Jan 08, 2024 10:59 am ET
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration of LOWE (Large Language Model-Orchestrated Workflow Engine), its new software designed to perform...
Jan 04, 2024 07:59 am ET
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’...
Jan 03, 2024 08:00 am ET
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris Gibson, Ph.D., Co-founder and CEO, will help kick off the 42nd Annual J.P. Morgan Healthcare Conference...
Dec 20, 2023 07:59 am ET
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to...
Dec 15, 2023 08:31 am ET
Thinking about buying stock in Aurora Technology Acquisition, Safety Shot, Uber Technologies, Verrica Pharmaceuticals, or Recursion Pharmaceuticals?
NEW YORK, Dec. 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATAK, SHOT, UBER, VRCA, and RXRX.
Nov 09, 2023 09:41 am ET
Bayer and Recursion Focus Research Collaboration on Oncology
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.  The...
Nov 09, 2023 08:01 am ET
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it...
Nov 09, 2023 07:58 am ET
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ending September 30, 2023. “Since our founding we...
Nov 02, 2023 08:05 am ET
Recursion to Participate in Upcoming Investor Conference
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,...
Sep 05, 2023 04:30 pm ET
Recursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Citi's 18th Annual BioPharma Conference – September 6-7,...
Sep 05, 2023 07:59 am ET
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of...
Aug 08, 2023 08:00 am ET
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has successfully screened the Enamine REAL Space chemical library using its MatchMaker technology, recently...
Aug 08, 2023 07:58 am ET
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023. "As the world continues to...
Aug 01, 2023 08:30 am ET
Recursion to Participate in Upcoming Investor Conference
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: KeyBanc Technology Leadership Forum – August 6-8,...
Jul 26, 2023 06:58 pm ET
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML). Valence Labs will serve as a machine...
Jul 19, 2023 09:31 am ET
Thinking about buying stock in Canoo, Recursion Pharmaceuticals, Knightscope, Deep Medicine Acquisition, or Digital World Acquisition?
NEW YORK, July 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOEV, RXRX, KSCP, DMAQ, and DWAC.
Jul 17, 2023 09:31 am ET
Thinking about buying stock in Nio Inc, Recursion Pharmaceuticals, Cenntro Electric, Healthcare Triangle, or Nova Lifestyle?
NEW YORK, July 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, RXRX, CENN, HCTI, and NVFY.
Jul 13, 2023 09:31 am ET
Thinking about trading options or stock in Canoo, GameStop, Cinemark Holdings, Recursion Pharmaceuticals, or Kingsoft Cloud Holdings?
NEW YORK, July 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOEV, GME, CNK, RXRX, and KC.
Jul 12, 2023 08:30 am ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion...
Jun 26, 2023 11:48 am ET
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its 28,000 square foot Toronto site, which will serve as the headquarters for Recursion Canada. The...
Jun 13, 2023 08:00 am ET
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the full enrollment of its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally...
Jun 07, 2023 10:45 am ET
Thinking about buying stock in Brainsway, Microvision, Recursion Pharmaceuticals, Dave & Buster's Entertainment, or Grid Dynamics?
NEW YORK, June 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BWAY, MVIS, RXRX, PLAY, and GDYN.
Jun 01, 2023 08:30 am ET
Recursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Goldman Sachs 44th Annual Global Healthcare Conference –...
May 25, 2023 04:00 pm ET
Altitude Lab Relocates to Gateway’s BioHive Hub
Altitude Lab announced today that its incubator program and facility will leave Research Park to grow its operation in the Gateway’s BioHive hub as part of Recursion’s recently expanded headquarters. The health care incubator will join biotechs...
May 16, 2023 08:30 am ET
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer. Dr. Mauro will lead Recursion’s pipeline...
May 08, 2023 08:14 am ET
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023. “Recursion has...
May 08, 2023 07:59 am ET
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence....
May 02, 2023 08:30 am ET
Recursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities 2023 Health...
Apr 03, 2023 08:30 am ET
Recursion to Participate in Upcoming Investor Conference
Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: 22nd Annual Needham Virtual Healthcare...
Mar 28, 2023 04:14 pm ET
Recursion Publishes Second Annual Environmental, Social and Governance Report
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced the release of its second annual Environmental, Social and Governance (ESG) Report. The report...
Mar 01, 2023 08:00 am ET
Recursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media &...
Feb 21, 2023 11:00 am ET
Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare Diseases
Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. On Rare Disease Day, Feb. 28, 2023, community...
Feb 01, 2023 07:01 am ET
Recursion to Participate in Upcoming Investor Conference
SALT LAKE CITY, Feb. 1, 2023 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:
Jan 26, 2023 07:30 am ET
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to useRxRx3, the underlying dataset released alongside MolRec™, spans almost the entire human genome and is 76 times larger than all previous datasets released by Recursion combined, yet it represents less than 1% of Recursion's total data universeSALT LAKE CITY, Jan. 26, 2023 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced the public relea
Dec 20, 2022 06:55 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, Dec. 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:
Nov 08, 2022 03:30 pm ET
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP)Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficile colitisNominated a new clinical program in AXIN1/APC mutant cancers with an initial focus on hepatocellular carcinoma and ovarian cancer, for which a Phase 2 clinical trial is being plannedRaised gross proceeds of approximately $150 million in a private placement offeringSALT LAKE CITY, Nov. 8, 2022 /PRNewswire/ -- Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug
Nov 02, 2022 07:59 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, Nov. 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:
Oct 25, 2022 08:00 am ET
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
SALT LAKE CITY, Oct. 25, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement, led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The price per share of $9.80 reflects an approximate 7% discount to the volume weighted avera
Sep 13, 2022 07:59 am ET
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP)Recursion initiates a Phase 1 trial for the potential treatment of Clostridium difficile (C. diff) Colitis with Recursion's first new chemical entity to enter the clinicSALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation of two additional clinical trials including its first in-house generated new chemical entity to enter the cli
Sep 01, 2022 07:55 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, Sept. 1, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:
Aug 18, 2022 07:55 am ET
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time Recursion has been ranked by ISS. The ISS ESG Corporate Rating provides an assessment of a company's environmental, social, and governance activity. A Prime Rating is awarded to companies with ESG performance above a sector-specific threshold and is defined by IS
Aug 09, 2022 04:15 pm ET
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomasOn track to initiate our Phase 2 clinical trial for the potential treatment of FAP in the third quarter of 2022U.S. FDA granted Recursion Fast Track designation and the European Commission granted Recursion Orphan Drug Designation for REC-4881 for the potential treatment of FAPOn track to initiate our Phase 1 clinical trial for the potential treatment of Clostridium difficile colitis in the second half of 2022SALT LAKE CITY, Aug. 9, 2022 /PRNewswire/ -- Recursion
Aug 02, 2022 07:55 am ET
Recursion to Participate in Upcoming Investor Conference
SALT LAKE CITY, Aug. 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:
Jul 21, 2022 07:55 am ET
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
SALT LAKE CITY, July 21, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan Drug Designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP). REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in FAP patients. 
Jun 20, 2022 07:55 am ET
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per yearREC-2282 has been granted Fast Track and Orphan Drug designations for NF2 meningiomas by the U.S. Food and Drug Administration, as well as Orphan Drug designation for NF2 meningiomas by the European CommissionSALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation of its Phase 2/3 PO
Jun 02, 2022 07:55 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, June 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
May 10, 2022 04:29 pm ET
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results
Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participantsExpecting to enroll the first participant in our Phase 2/3 clinical trial for progressive NF2-mutated meningiomas in the second quarter 2022Received Fast Track Designation for REC-4881, a potential treatment for FAP, and expect to enroll the first participant in a Phase 2 trial in the third quarter 2022SALT LAKE CITY, May 10, 2022 /PRNewswire/ -- Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business update
May 02, 2022 07:55 am ET
Recursion to Participate in Upcoming Investor Conference
SALT LAKE CITY, May 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conference:
Apr 26, 2022 08:31 am ET
Thinking about buying stock in Magnachip Semiconductor, Gamida Cell, GoldMining, Recursion Pharmaceuticals, or Avadel Pharmaceuticals?
NEW YORK, April 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MX, GMDA, GLDG, RXRX, and AVDL.
Apr 11, 2022 07:55 am ET
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to a
Mar 31, 2022 07:55 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, March 31, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
Mar 30, 2022 07:55 am ET
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
The total capital represents the largest seed financing for life science startups in Utah's history
Mar 24, 2022 07:55 am ET
Recursion Publishes First Environmental, Social and Governance (ESG) Report
Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardshipAnnounces new long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity and philanthropySALT LAKE CITY, March 24, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX) today announced the release of its inaugural Environmental, Social and Governance (ESG) Report, highlighting the company's approach, practices and goals in several important areas such as its people and culture, community engagement, commitment to patients and enviro
Mar 23, 2022 07:55 am ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicinesExpanded our collaboration with Bayer to include the use of Recursion's OS to map and navigate biology and increased the number of potential programs in fibrosis to more than a dozenEnrolled the first patient in our Phase 2 clinical trial for CCMAdvanced our internal pipeline of potential oncology therapeutics, including programs related to CDK12, target alpha, STK11, MYC, and
Mar 18, 2022 07:55 am ET
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5 SALT LAKE CITY, March 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the enrollment of the first patient in its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally bioa
Mar 03, 2022 06:55 am ET
Recursion Provides Updated Guidance on Clinical Trial Starts
SALT LAKE CITY, March 3, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts:
Mar 02, 2022 07:47 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, March 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
Feb 08, 2022 06:55 am ET
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, Feb. 8, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
Dec 07, 2021 06:55 am ET
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Method
SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced a transformational collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group. Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System (OS) to more rapidly identify novel targets and advance medicines in ke
Dec 06, 2021 06:55 am ET
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities
SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced expansion of the company's existing strategic collaboration in fibrosis with Bayer AG. The expanded collaboration will include Recursion's powerful inferential search capabilities based on its growing maps of human cellular biology, giving Bayer the ability to further accelerate the work already underway in expanding the universe of nove
Nov 30, 2021 06:55 am ET
Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments
SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced a deepening of its neuroscience expertise with key hires in human induced pluripotent stem cell (iPSC) biology, translational neuroscience and clinical development. Tim Ahfeldt, Ph.D. will serve as Fellow, Neuroscience; Irit Rappley, Ph.D. will serve as Vice President, Neuroscience and Translational Research; and Glenn Morrison, Ph.D.,
Nov 10, 2021 06:55 am ET
Recursion Provides Business Updates and Reports Third Quarter 2021 Financials
SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- Recursion (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering, today reported business updates and financial results for its third quarter ending September 30, 2021.
Oct 07, 2021 07:55 am ET
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas
SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas. REC-2282 is a potentially first-in-class, orally bioavailable, CNS-penetrant small molecule
Sep 29, 2021 08:54 am ET
Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
SALT LAKE CITY, Sept. 29, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP). REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce tumor size in FAP patient
Aug 13, 2021 07:55 am ET
Recursion Reports Second Quarter 2021 Financials and Provides Business Updates
SALT LAKE CITY, Aug. 13, 2021 /PRNewswire/ -- Recursion (Nasdaq: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021.
Jul 13, 2021 07:55 am ET
Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD
SALT LAKE CITY, July 13, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. The TAB will guide Recursion's executive team and Board of Directors on the key challenge of developing medicines at scale from its tech-enabled drug discovery pipeline and bringing them to the patients who need them the most.
Jul 12, 2021 04:41 pm ET
Recursion Opens Child Care Center to Support Employees
SALT LAKE CITY, July 12, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced the opening of its child care center, adjacent to Recursion's Salt Lake City headquarters.
Jul 01, 2021 08:54 am ET
Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City
SALT LAKE CITY, July 1, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and office space as well as 1,200 multifamily units.
Jun 23, 2021 08:53 am ET
Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems
Jun 23, 2021 08:53 am ET
Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems
Jun 15, 2021 08:54 am ET
Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology.
Jun 15, 2021 08:54 am ET
Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.